Literature DB >> 29431639

CXCL12γ Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes.

Younghun Jung1, Frank C Cackowski1,2, Kenji Yumoto1, Ann M Decker1, Jingcheng Wang1, Jin Koo Kim3,4, Eunsohl Lee1, Yugang Wang5, Jae-Seung Chung5,6, Amy M Gursky5, Paul H Krebsbach3,4, Kenneth J Pienta7, Todd M Morgan5, Russell S Taichman8.   

Abstract

There is evidence that cancer stem-like cells (CSC) and neuroendocrine behavior play critical roles in the pathogenesis and clinical course of metastatic castration-resistant prostate cancer (m-CRPC). However, there is limited mechanistic understanding of how CSC and neuroendocrine phenotypes impact the development of m-CRPC. In this study, we explored the role of the intracellular chemokine CXCL12γ in CSC induction and neuroendocrine differentiation and its impact on m-CRPC. CXCL12γ expression was detected in small-cell carcinoma of metastatic tissues and circulating tumor cells from m-CRPC patients and in prostate cancer cells displaying an neuroendocrine phenotype. Mechanistic investigations demonstrated that overexpression of CXCL12γ induced CSC and neuroendocrine phenotypes in prostate cancer cells through CXCR4-mediated PKCα/NFκB signaling, which promoted prostate tumor outgrowth, metastasis, and chemoresistance in vivo Together, our results establish a significant function for CXCL12γ in m-CRPC development and suggest it as a candidate therapeutic target to control aggressive disease.Significance: Expression of CXCL12γ induces the expression of a cancer stem cell and neuroendocrine phenotypes, resulting in the development of aggressive m-CRPC. Cancer Res; 78(8); 2026-39. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29431639      PMCID: PMC6324566          DOI: 10.1158/0008-5472.CAN-17-2332

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  58 in total

Review 1.  A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms.

Authors:  Monica Cojoc; Katrin Mäbert; Michael H Muders; Anna Dubrovska
Journal:  Semin Cancer Biol       Date:  2014-06-20       Impact factor: 15.707

2.  Chemokine and chemokine receptor expression in kidney tumors: molecular profiling of histological subtypes and association with metastasis.

Authors:  Jeffrey C Gahan; Miguel Gosalbez; Travis Yates; Ezekiel E Young; Diogo O Escudero; Andrew Chi; Michael Garcia-Roig; Ramgopal Satyanarayana; Mark S Soloway; Vincent G Bird; Vinata B Lokeshwar
Journal:  J Urol       Date:  2012-01-15       Impact factor: 7.450

3.  Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo.

Authors:  Yan-Xi Sun; Abraham Schneider; Younghun Jung; Jianhua Wang; Jinlu Dai; Jingcheng Wang; Kevin Cook; Nadir I Osman; Amy J Koh-Paige; Hyusuk Shim; Kenneth J Pienta; Evan T Keller; Laurie K McCauley; Russell S Taichman
Journal:  J Bone Miner Res       Date:  2004-11-16       Impact factor: 6.741

4.  Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer.

Authors:  Ganesh S Palapattu; Chengyu Wu; Christopher R Silvers; Heather B Martin; Karin Williams; Linda Salamone; Timothy Bushnell; Li-Shan Huang; Qi Yang; Jiaoti Huang
Journal:  Prostate       Date:  2009-05-15       Impact factor: 4.104

5.  Dramatically elevated circulating tumor cell numbers in a patient with small cell neuroendocrine carcinoma of the prostate.

Authors:  Fanny Chan; Oscar Goodman; Louis Fink; Nicholas J Vogelzang; David Pomerantz; Joseph D Khoury
Journal:  Arch Pathol Lab Med       Date:  2010-01       Impact factor: 5.534

6.  Immunocytochemical localization of eight protein kinase C isozymes overexpressed in NIH 3T3 fibroblasts. Isoform-specific association with microfilaments, Golgi, endoplasmic reticulum, and nuclear and cell membranes.

Authors:  J A Goodnight; H Mischak; W Kolch; J F Mushinski
Journal:  J Biol Chem       Date:  1995-04-28       Impact factor: 5.157

7.  Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis.

Authors:  Younghun Jung; Jin Koo Kim; Yusuke Shiozawa; Jingcheng Wang; Anjali Mishra; Jeena Joseph; Janice E Berry; Samantha McGee; Eunsohl Lee; Hongli Sun; Jianhua Wang; Taocong Jin; Honglai Zhang; Jinlu Dai; Paul H Krebsbach; Evan T Keller; Kenneth J Pienta; Russell S Taichman
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

8.  CXCL12/CXCR4 signaling counteracts docetaxel-induced microtubule stabilization via p21-activated kinase 4-dependent activation of LIM domain kinase 1.

Authors:  Arun Bhardwaj; Sanjeev K Srivastava; Seema Singh; Sumit Arora; Nikhil Tyagi; Joel Andrews; Steven McClellan; James E Carter; Ajay P Singh
Journal:  Oncotarget       Date:  2014-11-30

Review 9.  Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure.

Authors:  Chang-Deng Hu; Richard Choo; Jiaoti Huang
Journal:  Front Oncol       Date:  2015-04-14       Impact factor: 6.244

Review 10.  The many faces of neuroendocrine differentiation in prostate cancer progression.

Authors:  Stéphane Terry; Himisha Beltran
Journal:  Front Oncol       Date:  2014-03-25       Impact factor: 6.244

View more
  16 in total

Review 1.  Bone microenvironment signaling of cancer stem cells as a therapeutic target in metastatic prostate cancer.

Authors:  Clara H Lee; Ann M Decker; Frank C Cackowski; Russell S Taichman
Journal:  Cell Biol Toxicol       Date:  2019-06-27       Impact factor: 6.691

Review 2.  Chemokines orchestrate tumor cells and the microenvironment to achieve metastatic heterogeneity.

Authors:  Sugandha Saxena; Rakesh K Singh
Journal:  Cancer Metastasis Rev       Date:  2021-05-06       Impact factor: 9.264

3.  Direct interaction of β-catenin with nuclear ESM1 supports stemness of metastatic prostate cancer.

Authors:  Ke-Fan Pan; Wei-Jiunn Lee; Chun-Chi Chou; Yi-Chieh Yang; Yu-Chan Chang; Ming-Hsien Chien; Michael Hsiao; Kuo-Tai Hua
Journal:  EMBO J       Date:  2020-12-21       Impact factor: 11.598

Review 4.  Cytokines and Chemokines as Mediators of Prostate Cancer Metastasis.

Authors:  Timothy O Adekoya; Ricardo M Richardson
Journal:  Int J Mol Sci       Date:  2020-06-23       Impact factor: 5.923

Review 5.  Chemokines and their Receptors: Multifaceted Roles in Cancer Progression and Potential Value as Cancer Prognostic Markers.

Authors:  Ha Thi Thu Do; Chang Hoon Lee; Jungsook Cho
Journal:  Cancers (Basel)       Date:  2020-01-24       Impact factor: 6.639

6.  Dual CXCR4 and E-Selectin Inhibitor, GMI-1359, Shows Anti-Bone Metastatic Effects and Synergizes with Docetaxel in Prostate Cancer Cell Intraosseous Growth.

Authors:  Claudio Festuccia; Andrea Mancini; Giovanni Luca Gravina; Alessandro Colapietro; Antonella Vetuschi; Simona Pompili; Luca Ventura; Simona Delle Monache; Roberto Iorio; Andrea Del Fattore; William Fogler; John Magnani
Journal:  Cells       Date:  2019-12-20       Impact factor: 6.600

7.  The paracrine induction of prostate cancer progression by caveolin-1.

Authors:  Chun-Jung Lin; Eun-Jin Yun; U-Ging Lo; Yu-Ling Tai; Su Deng; Elizabeth Hernandez; Andrew Dang; Yu-An Chen; Debabrata Saha; Ping Mu; Ho Lin; Tsai-Kun Li; Tang-Long Shen; Chih-Ho Lai; Jer-Tsong Hsieh
Journal:  Cell Death Dis       Date:  2019-11-04       Impact factor: 8.469

Review 8.  CXCL12 Signaling in the Tumor Microenvironment.

Authors:  Luigi Portella; Anna Maria Bello; Stefania Scala
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 9.  At the Bench: Pre-clinical evidence for multiple functions of CXCR4 in cancer.

Authors:  Gary D Luker; Jinming Yang; Ann Richmond; Stefania Scala; Claudio Festuccia; Margret Schottelius; Hans-Jürgen Wester; Johann Zimmermann
Journal:  J Leukoc Biol       Date:  2020-10-26       Impact factor: 4.962

10.  ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4.

Authors:  Tianxing Zhou; Jing Liu; Yongjie Xie; Shuai Yuan; Yu Guo; Weiwei Bai; Kaili Zhao; Wenna Jiang; Hongwei Wang; Haotian Wang; Tiansuo Zhao; Chongbiao Huang; Song Gao; Xiuchao Wang; Shengyu Yang; Jihui Hao
Journal:  Gut       Date:  2021-03-05       Impact factor: 31.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.